Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
13Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Q32 Bio Inc. (QTTB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
22Total relationships
3Distinct source URLs
9High confidence
0.764Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Q32 Bio Inc. Suppliers
Ticker
Name
Confidence
Evidence
BMY
Bristol-Myers Squibb Company
92%
Reciprocal relationship from BMY graph: Reciprocal relationship from QTTB graph: we obtained sublicensable licenses from BMS to research, develop and commercialize licensed products, including bempikibart
BMY
Bristol-Myers Squibb Company
92%
we obtained sublicensable licenses from BMS to research, develop and commercialize licensed products, including bempikibart
CANTOR-FITZGERALD-CO
CANTOR-FITZGERALD-CO
92%
The Company will pay the Sales Agent a cash commission of 3.0% of gross proceeds from the sale of the Shares pursuant to the Sales Agreement.
HORIZON-THERAPEUTICS-IRELAND-DAC
HORIZON-THERAPEUTICS-IRELAND-DAC
90%
Legacy Q32 was a party to the Horizon Agreements with Horizon, pursuant to which Legacy Q32 received $55.0 million
OXB-US-LLC
OXB-US-LLC
80%
the Company obt ained Homology's 20 % equity interest in OXB (US) LLC, an AAV vector process development and manufacturing services company
HOMOLOGY
HOMOLOGY
70%
The Company concluded that the CVR liability was a derivative liability and was accounted for at fair value. The fair value of the CVR liability was based on significant unobservable inputs, which re…
Q32 Bio Inc. Customers
Ticker
Name
Confidence
Evidence
OXFORD-BIOMEDICA-US-INC
OXFORD-BIOMEDICA-US-INC
90%
On March 1, 2025, Oxford Biomedica (US), Inc. exercised its option to cause the Company to sell and transfer to Oxford Biomedica (US), Inc. all of the Company’s equity ownership interest in OXB (US) LLC
BMY
Bristol-Myers Squibb Company
72%
respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans…
BMY
Bristol-Myers Squibb Company
72%
Reciprocal relationship from BMY graph: Reciprocal relationship from QTTB graph: respect to the development of any of our product candidates could significantly change the costs and timing associated…
BMYMP
Bristol-Myers Squibb Co
72%
respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans…
BMYMP
Bristol-Myers Squibb Co
72%
Reciprocal relationship from BMYMP graph: Reciprocal relationship from QTTB graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from QTTB graph: respect to the development of any…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from QTTB graph: mpleted any late-stage clinical trials and we may not be able to submit applications for regulatory authorizations t…
SNYNF
Sanofi
72%
mpleted any late-stage clinical trials and we may not be able to submit applications for regulatory authorizations to commence additional clinical trials on the timelines we expect, and, even if we a…
AKEBIA-THERAPEUTICS-INC
AKEBIA-THERAPEUTICS-INC
62%
payments in a lease arrangement. Variable lease costs are expensed as incurred. The incremental borrowing rate represents the interest rate at which the Company could borrow a fully collateralized am…
BRISTOL-MYERS-SQUIBB-COMPANY
BRISTOL-MYERS-SQUIBB-COMPANY
62%
mpleted any late-stage clinical trials and we may not be able to submit applications for regulatory authorizations to commence additional clinical trials on the timelines we expect, and, even if we a…
HOMOLOGY-MEDICINES-INC
HOMOLOGY-MEDICINES-INC
62%
ate offering price of up to $ 75 million pursuant to the Sales Agreement. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnolog…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth…
Q32-BIO-OPERATIONS-INC
Q32-BIO-OPERATIONS-INC
62%
payments in a lease arrangement. Variable lease costs are expensed as incurred. The incremental borrowing rate represents the interest rate at which the Company could borrow a fully collateralized am…
US-LLC
US-LLC
62%
d and carried at fair value during the three months ended March 31, 2026 and 2025 . 6. Investment in Equity Securities As part of the Merger, the Company obt ained Homology's 20 % equity interest in …
Q32 Bio Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
QTTB-DEBT
Debt stack $13.6M
90%
Market cache reports total debt of $13.6M.
QTTB-DEBT-12020
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
Q32 Bio Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Q32 Bio Inc..
Q32 Bio Inc. Ownership
Holder
Name
Confidence
Evidence
QTTB-OWNER-ORBIMED-ADVISORS-LLC
ORBIMED ADVISORS LLC
90%
13F overlay lists ORBIMED ADVISORS LLC as top holder; 55 tracked holders.
